FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2505-2507 December 8, 2005 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Becker, M. A. PubMed Citation

Gout is a relatively common cause of legendary, severe pain as well as tophi, joint deformities, and nephropathy. Unlike most noninfectious diseases, frequently a pharmacologic "cure" for gout is attained. Shortcomings in the management of gout — due to poor patient education and compliance, substandard medical management, and drug toxicity — can perpetuate its adverse effects. The burden of gout is substantial, and recent epidemiologic studies suggest that it is increasing. This increase is probably due to risk factors related to lifestyle.^1,2

Acute and chronic arthritis, tophi, and renal disease are manifestations of gout that reflect the magnitude and duration . . . [Full Text of this Article]

Source Information

From the University of Alabama at Birmingham School of Medicine, Birmingham.

This article has been cited by other articles:

• Reinders, M K, Haagsma, C, Jansen, T L T. A, van Roon, E N, Delsing, J, van de Laar, M A F J, Brouwers, J R B J (2009). A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 68: 892-897 [Abstract] [Full Text]